Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Ipsen appoints Michelle C. Werner as EVP, President of North America

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

Ipsen nominates Peter Guenter to its Board of Directors

Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team

Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia

Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate